Skip to content

Sarepta Therapeutics

US · SRPT #2853 by market cap Listed 1970
13.33 -0.84 -5.93%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:54

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions decreased by 6 in the most recent period (2026/Q3).
  • Total institutional ownership fell 4.8 percentage points.

Ownership vs. money flow

Aligned

Institutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
98.06% -4.79pp
Institutions
385 -6
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund70.72%
Hedge Fund17.51%
Public Company5.80%
Individual/Insider4.70%
Private Company1.56%
Government Pension Fund1.44%
Insurance Company0.49%
VC/PE Fund0.45%

Top holders as of 2026-09-30

BlackRock 17.51% · 18.78M sh
Vanguard Portfolio Management, LLC 8.11% · 8.70M sh
State Street Global Advisors 6.91% · 7.41M sh
Vanguard Capital Management, LLC 4.29% · 4.60M sh
Two Sigma Investments, LP 4.29% · 4.60M sh
First Trust Advisors L.P. 4.07% · 4.37M sh
AQR Capital Management 3.98% · 4.27M sh
Richard Barry 3.00% · 3.22M sh
Geode Capital Management, LLC 2.51% · 2.69M sh
Erste Asset Management GmbH 2.12% · 2.27M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 26 buys · 24 sells

NameRoleStake
Richard Barry Independent Director 3.00%
Michael Chambers Independent Director 0.45%
Douglas Ingram Advisor 0.36%
M. Behrens Wilsey Independent Chairwoman 0.19%
Louise Rodino-Klapac President of Research & Development and Technical Operations 0.19%
Ian Estepan President 0.17%
Ryan Wong Chief Financial Officer 0.11%
Cristin Rothfuss -- 0.11%
Claude Nicaise Independent Director 0.03%
Hans Wigzell Chairman of Corporate Strategy Board & Independent Non-Employee Director 0.02%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-09-03 Louise Rodino-Klapac President of Research & Development and Technical Operations Sale to Issuer -21,423 $22.22
2026-09-03 Ian Estepan President Sale to Issuer -24,799 $22.22
2026-09-03 Cristin Rothfuss -- Sale to Issuer -22,025 $22.22
2026-09-03 Ryan Wong Chief Financial Officer Sale to Issuer -13,272 $22.22
2026-07-27 Michael Severino Chief Executive Officer Other Acquisition +756,104 --
2026-07-27 Michael Severino Chief Executive Officer Other Derivative Acquisition +2,224,342 $17.74
2026-06-03 M. Behrens Wilsey Independent Chairwoman Other Acquisition +16,875 --
2026-06-03 Hans Wigzell Chairman of Corporate Strategy Board & Independent Non-Employee Director Other Acquisition +16,875 --
2026-06-03 Richard Barry Independent Director Other Acquisition +16,875 --
2026-06-03 Michael Chambers Independent Director Other Acquisition +16,875 --
2026-06-03 Deirdre Connelly Independent Director Other Acquisition +16,875 --
2026-06-03 Stephen Mayo Independent Director Other Acquisition +16,875 --
2026-06-03 Claude Nicaise Independent Director Other Acquisition +16,875 --
2026-06-03 Kathryn Boor Independent Director Other Acquisition +16,875 --
2026-03-11 Stephen Mayo Independent Director Open Market Disposition -7,239 $17.02
2026-03-10 Louise Rodino-Klapac President of Research & Development and Technical Operations Sale to Issuer -948 $17.03
2026-03-10 Ian Estepan President Sale to Issuer -1,097 $17.03
2026-03-10 Cristin Rothfuss -- Sale to Issuer -974 $17.03
2026-03-10 Ryan Wong Chief Financial Officer Sale to Issuer -256 $17.03
2026-03-08 Louise Rodino-Klapac President of Research & Development and Technical Operations Sale to Issuer -1,399 $16.95

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:54:28 · For reference only, not investment advice and not tailored to your situation.

Sarepta Therapeutics discussion 0 comments

Add a comment